Aslan Pharmaceuticals Ltd ASLN 深 沪
已收盘 07-18 16:00:00 美东时间
0.60
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.60
- 总市值 4184.68万
- 52周最高 4.23
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.2715
- 委 比 0.00%
- 总股本 6974.47万
- 历史最高 10.439
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.2715
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
Ascentage Pharma announced that 13 studies of its core assets, including olverembatinib, lisaftoclax, and APG-5918, will be presented at the 2025 European Hematology Association (EHA) Annual Congress in Milan. The studies cover cutting-edge research in hematology and highlight the company's dedication to addressing unmet medical needs in cancer treatments.
06-09 23:30
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
Ascentage Pharma announced positive clinical data for its Bcl-2 inhibitor, lisaftoclax, and MDM2-p53 inhibitor, alrizomadlin, to be presented at the 2025 ASCO Annual Meeting. Both drugs demonstrated antitumor activity and tolerability in Phase 1b/2 and Phase 2 studies, supporting their further development for various cancers.
05-23 00:15
